Voyager Therapeutics (VYGR) Tops Q4 EPS by 5c

Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.46), $0.05 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $15.34 million versus the consensus estimate of $9.19 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Blue Owl leads $2.4B equipment financing for IREN's Canada data center
• Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak